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ORIGINAL ARTICLE
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ABSTRACT
Background: Meningiomas are usually slow growing, well circumscribed intracranial tumors. In symp-
tom-free cases observation with close follow-up imaging could be performed. Symptomatic meningio-
mas could be surgically removed and/or treated with radiotherapy. The study aimed to evaluate the
volumetric response of intracranial meningiomas at different time points after photon, proton, and a
mixed photon and carbon ion boost irradiation.
Patients and methods: In Group A 38 patients received proton therapy (median dose: 56 GyE in 1.8–2
GyE daily fractions) or a mixed photon/carbon ion therapy (50Gy in 2Gy daily fractions with intensity
modulated radiotherapy (IMRT) and 18 GyE in 3 GyE daily dose carbon ion boost). Thirty-nine patients
(Group B) were treated by photon therapy with IMRT or fractionated stereotactic radiotherapy tech-
nique (median dose: 56Gy in 1.8–2Gy daily fractions). The delineation of the tumor volume was based
on the initial, one- and two-year follow-up magnetic resonance imaging and these volumes were com-
pared to evaluate the volumetric tumor response.
Results: Significant tumor volume shrinkage was detected at one- and at two-year follow-up both after
irradiation by particles and by photons. No significant difference in tumor volume change was
observed between photon, proton or combined photon plus carbon ion boost treated patients. WHO
grade and gender appear to be determining factors for tumor volume shrinkage.
Conclusion: Significant volumetric shrinkage of meningiomas could be observed independently of the
applied radiation modality. Long-term follow-up is recommended to evaluate further dynamic of size
reduction and its correlation with outcome data.
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Meninigiomas are usually slow growing, well circumscribed
and benign tumors deriving from arachnoidal cells. They are
the most common primary non-glial brain tumors in adults
and account for 15–30% of all intracranial neoplasms [1,2].
Despite their generally benign character, they are often
neighboring or infiltrating critical neurovascular structures
and their growth can cause neurological or neurocognitive
deficits leading to a significant worsening in quality of life.
Gross total resection (GTR) provides long-term recurrence-
free survival in many cases [3,4]. If only subtotal resection
(STR) can be achieved or in cases of grade II tumors, adjuvant
radiotherapy (RT) should be considered. In cases of anaplastic
meningiomas RT should be always a part of the therapy [5,6].
Beside surgical resection highly conformal RT has also
become a primary treatment alternative over the last deca-
des. Due to improvements in treatment planning and
technical application of high precision photon RT, fractio-
nated stereotactic radiotherapy (FSRT) and intensity modu-
lated radiotherapy (IMRT) have been well established.
These techniques showed convincing local control (75–100%)
and very low side effect rates [7–10].
Since November 2009, protons and carbon ions are avail-
able at the Heidelberg Ion-Beam Therapy Center (HIT). RT
with charged particles offers high precision dose deposition
in a defined depth (Bragg peak). The raster scanning tech-
nique allows maximal homogeneous irradiation of the tumor
while minimizing the dose to the surrounding healthy struc-
tures as organs at risk (OARs). Furthermore, the high linear
energy transfer (LET) of carbon ions causes dense ionization
resulting in an increased relative biological effectiveness
(RBE) in radiorersistant tumors, which is about 2–5 times
higher than in photon therapy [11].
As a result of the mostly benign character of meningiomas
and a relatively long life expectancy of patients suffering
from this disease, it is essential to avoid radiation-induced
late side effects. With highly conformal RT a maximum pre-
vention of the OARs can be achieved. As meningiomas are
known to be relatively radioresistant and are often adjacent
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to critical nervous structures, ion therapy is expected to be
particularly suitable for their treatment [12]. Our previous
data have already demonstrated promising results after
irradiation of meningiomas by particles [13–15].
In the past, several groups have evaluated the
volumetric response of intracranial meningiomas after pho-
ton RT [16,17]. Up to now, no work has been published using
particle therapy. Hence, the aim of this study was to evaluate
the volumetric response after both proton and carbon ion
irradiation and to compare the results with photon
irradiation.
Patients and methods
Two groups of 77 patients, chosen from a large database
[18], suffering from inoperable (even biopsy was not feasible;
grade of meningioma is unknown), residual or recurrent
meningioma, treated in two time periods with different radi-
ation modalities, were analyzed and compared retrospect-
ively. The performance of this study was approved by the
local ethics committee (Ethikkommission Medizinische
Fakult€at Heidelberg). In the first group (Group A) patients
were randomly chosen from the database [18]. They received
proton therapy or carbon ion boost according to a defined
protocol [15]. Patients with similar characteristics (age, gen-
der, tumor volume, etc.) treated by photon therapy (IMRT or
FSRT) were chosen (Group B) to compare the dynamics of
tumor response.
Group A consists of 38 patients who were treated at the
HIT between September 2010 and January 2012 due to inop-
erable (10/38), residual (6/38) or recurrent (22/38) meningio-
mas. Histological WHO grade was unknown in 10/38, grade I
in 17/38, grade II in 10/38 and grade III in 1/38 patients.
Median age at the time of RT was 52.5 years (range
32.1–76.8 years). Male to female ratio was 9:29. The tumors
were located at the skull base in 31/38, attached to the
olfactory tract in 4/38, at the falx in 2/38 or in the orbit in
1/38 patients. Proton RT was delivered to the macroscopic
tumor with a safety margin in benign cases (unknown and
grade I 27/38) with a median dose of 56 GyE (range
54–58Gy) in 1.8 or 2 GyE daily fractions. For high grade men-
ingiomas (grade II and III 11/38) a mixed photon/carbon ion
scheme according to the MARCIE protocol was used: 50Gy in
2Gy daily fractions with IMRT and 18 GyE in 3 GyE daily dose
carbon ion boost to the macroscopic tumor [15].
In the past, several hundred patients were treated by
IMRT or FSRT for their intracranial meningioma at the
Department of Radiation Oncology of the University Hospital
Heidelberg [6,9,12]. From these, 39 patients were selected
who had been treated between November 2000 and July
2009 and matched best regarding the clinical parameters
(age, gender, tumor volume, etc.) (Group B). They were irradi-
ated because of inoperable (12/39), residual (10/39) or recur-
rent (17/39) meningiomas. Histological grade was unknown
in 12/39, grade I in 16/39, grade II in 7/39 and grade III in
4/39 patients. Median age at the time of RT was 55.2 years
(range 20.6–80.8 years). Male to female ratio was 11:28.
Meningiomas were located at the skull base in 25/39, at the
convexity in 5/39, in the cavernous sinus in 4/39, at the falx
in 2/39, on the optic nerve in 2/39 or at the craniocervical
junction in 1/39 patients. IMRT or FSRT was applied with a
median dose of 56Gy (range 39.6–60Gy) in 1.8 or 2Gy daily
fractions (Table 1).
Patients were individually affixed with special head masks
(Scotch Cast- or Thermoplast-masks) as described previously
[9,14]. For delineation of OARs and gross tumor volume
(GTV) a trimodal image fusion of a contrast-enhanced com-
puted tomography (CT) scan with 3mm slices, a T1 weighted,
contrast-enhanced magnetic resonance imaging (MRI) and a
DOTATOC-positron emission tomography (PET) was used, as
this procedure was shown to be benificial in many cases
[13,19–21].
Table 1. Patients' characteristics.
Proton IMRTþ C12 boost IMRT FSRT
Patients (n) 27 11 16 23
Gender m:f (n) 4:23 5:6 5:11 6:17
WHO Grade (n)
Unknown 10 – 4 8
I 17 – 7 9
II – 10 3 4
III – 1 2 2
Localization (n)
Skull base 23 8 13 12
Olfactory tract 3 1
Falx cerebri – 2 – 2
Orbita – 1
Convexity – – 2 3
Cavernous sinus – – – 4
N. opticus – – – 2
Craniocervical junction – – 1 –
Cause of RT (n)
Inoperable 10 0 4 8
Residual 3 3 3 7
Recurrent 14 8 9 8
In. Vmean (cm
3) 26.1 ± 22.2 26.5 ± 15.4 37.3 ± 29.5 26.7 ± 23.1
1y Vmean (cm
3) 23.5 ± 19.8 20.9 ± 14.4 34.6 ± 28.0 20.5 ± 14.3
Rel. TV at 1y (%) 86.4 ± 15.6 77.9 ± 22.0 89.2 ± 24.9 84.0 ± 22.9
2ys Vmean (cm
3) 24.3 ± 20.7 12.9 ± 10.0 23.5 ± 17.5 13.9 ± 10.0
Rel. TV at 2y (%) 86.2 ± 9.2 70.1 ± 23.5 69.4 ± 17.7 77.0 ± 14.6
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For photon and proton RT the clinical target volume (CTV)
included the GTV as well as a safety margin depending on
histology was added as described previously (1–3mm in
cases of low grade pathology and 10–20mm in atypical and
anaplastic tumors) [6]. Anatomical borders were respected.
According to the MARCIE trial, a 5mm safety margin was
given to the GTV for the carbon ion boost RT. For all patients
the planning target volume (PTV) was calculated with an
additional margin of 2–3mm in Thermoplast- or 1–2mm in
Scotch Cast masks-setup (Figure 1).
After RT, patients were enrolled in a continuous and regu-
lar follow-up program: thorough clinical-neurological examin-
ation and contrast-enhanced MRI following our in-house
standard. The first- and second-year follow-up MRIs were
compared with the pre-therapeutic one in each patient to
evaluate the volumetric tumor response for this study.
Therefore, the GTV was delineated on the initial pre-thera-
peutical MRI as well as on the first- and second-year follow-
up MRIs in cooperation of two experienced radiation
oncologists using Siemens Dosimetrist (Siemens Medical
Solutions, Concord, CA). Afterwards, these three GTVs (pre-
therapeutical, first- and second-year follow-up) were com-
pared and tumor volumes (TV) were calculated in cm3
(Masterplan Oncentra, Nucletron, Columbia, MD).
The statistical analysis was performed with SPSS 20. Paired
and two samples t-tests as well as ANOVA tests were done.
Results
Every patient completed RT without a long interruption.
Detailed treatment outcome of the patients has been pub-
lished from our institution in the past [6,9,12,13,15,22].
In Group A, 27 patients were treated by proton RT. The
mean initial TV was Vmean¼ 26.1 ± 22.2 cm3. There was a sig-
nificant absolute TV shrinkage after one year (Vmean¼
23.5 ± 19.8 cm3; Vchange mean¼3.7 ± 4.6 cm3, p¼ .001). At the
two-year follow-up a steady state could be observed com-
pared to the volumes after one year (Vmean¼ 24.3 ± 20.7 cm3).
Figure 1. Treatment plans of three patients: IMRT (A), protons (B), and carbon ion boost according to MARCIE protocol (C).
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Eleven patients were treated by carbon ion boost combined
with IMRT. The mean inital TV was Vmean¼ 26.5 ± 15.4 cm3.
There was a siginificant absolute TV shrinkage at one-year
follow-up (Vmean¼ 20.9±14.4 cm3; Vchange mean¼5.7± 5.6 cm3,
p¼ .011). At two-year follow-up the contrast enhancing vol-
ume had decreased (Vmean¼ 12.9 ±10.0 cm3), however, this
shrinkage was not significant (p¼ .083). There was no signifi-
cant difference in TV changes between combined IMRT plus
carbon ion boost and proton-treated patients.
In Group B, 16 patients were treated by IMRT. The mean
initial TV was Vmean¼ 37.3 ± 29.5 cm3. There was a
significant absolute TV shrinkage both after one year
(Vmean¼ 34.6 ± 28.0 cm3; Vchange mean¼4.3 ± 4.1 cm3,
p¼ .003) and at the two-year follow-up
(Vmean¼ 23.5 ± 17.5 cm3; Vchange mean¼9.0 ± 5.2 cm3,
p¼ .017). There was a significant absolute shrinkage after
two years compared to the one-year follow-up as well
(Vchange mean¼3.4 ± 1.5 cm3, p¼ .020).
Twenty-three patients were treated by FSRT. The mean
inital TV was Vmean¼ 26.7 ± 23.1 cm3. There was a
siginificant absolute TV shrinkage both after one year
(Vmean¼ 20.5±14.3 cm3; Vchange mean¼7.0±14.7 cm3, p¼ .042)
and at the two-year follow-up (Vmean¼ 13.9±10.0 cm3;
Vchange mean¼4.7±3.9 cm3, p¼ .001). There was a significant
absolute shrinkage at two-year compared to one-year follow-up
as well (Vchange mean¼1.3±1.8 cm3, p¼ .038). There was no
significant difference in TV changes between IMRT- and FSRT-
treated patients (Figures 2 and 3, Table 1).
A significant absolute TV shrinkage was found in male as
well as in female patients. In men (20/77) the mean inital TV
was Vmean¼ 40.6 ± 31.4 cm3, after one year Vmean¼
34.0 ± 27.4 cm3 (p¼ .018) and after two years Vmean¼
19.5 ± 13.2 cm3 (p< .0001). In women (57/77) the mean inital
TV was Vmean¼ 24.5 ± 18.4 cm3, at one-year follow-up
Vmean¼ 21.6 ± 16.4 cm3 (p< .001) and two-year follow-up
Vmean¼ 17.5 ± 16.2 cm3 (p< .0001). Men showed a significant
higher shrinkage after irradiation by both modalities and
at both follow-up examinations. In male patients the
Vchange mean was 10.1 ± 15.8 cm3 and 7.8 ± 4.6 cm3 after
one and two years, respectively. In women it was
Vchange mean¼3.5±4.3 cm3 and 3.9±3.3 cm3 (Mann-Whitney
U-test p¼ .028, p¼ .022) (Figure 4). Therefore, gender was
found to be an independent predictive factor for TV change.
In patients with grade III meningioma (5/77, initial
Vmean¼ 31.4 ± 21.5 cm3) we observed significantly higher rela-
tive TV shrinkage in comparison to patients with unknown
histology (22/77, initial Vmean¼ 22.2 ± 15.1 cm3) as well as to
patients with grade I meningiomas (33/77, initial
Vmean¼ 30.0 ± 25.1 cm3), both at one-year (p¼ .045 and
p¼ .038) and two-year follow-up (p¼ .010 and p¼ .012). The
mean relative size of the residual, contrast enhancing TV was
58.0 ± 22.9% and 52.1 ± 13.5% in the grade III cases after one
and two years. In patients with unknown histology the
residual TV was 89.6 ± 19.9% and 81.7 ± 6.6% as well as
89.3 ± 17.3% and 83.0 ± 13.6% in grade I meningiomas,
respectively. Patients with grade II meningioma showed a
higher tumor shrinkage at one- and two-year follow-up than
patients with unknown or with grade I meningioma, but less
tumor volume reduction than grade III. No significancy could
be performed between the group of grade II meningioma in
comparison with the unknown or grade I and grade III
tumors (Figure 5).
Neither age, radiation modality (photon vs. particle), initial
TV nor operability were found to be significant independent
predictive factors for volumetric response at the two-year fol-
low-up.
Discussion
The aim of this retrospective study was to compare the volu-
metric changes of meningiomas one and two years after
treatment by different RT modalities. This is the first evalu-
ation of volumetric response of intracranial meningiomas
Figure 2. Absolute TV changes according to RT modalities.
434 P. MOZES ET AL.
after irradiation by particles and the first analysis comparing
the change of TV after different RT modalities.
We could show that both high precision photon RT and
irradiation by charged particles alone or in combination with
photon RT lead to a significant measurable TV reduction in
first and second year after RT. In the patient group where RT
was performed with protons a steady state could be observed
between the volumes at one and two years contoured on the
follow-up MRI images. Further follow-up might provide more
detailed results about volumetric changes. In all but one
patient a size reduction of the TV was detected both on the
one- and two-year follow-up MRIs. Mean tumor shrinkage of
about 25% was measured after two years over all treatment
modalities. In patients with tumor-related neurological
disorders caused by affection of sensitive neighboring struc-
tures this seems to be too slow to avoid persistent deficits. In
these cases RT does not seem to be the first treatment of
choice, if an early neurosurgical resection could prevent the
patient from long-term sequelae [1,4]. In patients with inoper-
able tumors or after STR RT can be considered as a primary or
as an adjuvant treatment [1,7]. In grade III tumors adjuvant RT
significantly improves progression-free (PFS) and overall sur-
vival (OS) even if GTR could be performed [23]. In grade II
meningiomas treatment concepts are still controversial. If STR
was feasible, RT can be delivered with an additive approach,
or it can be delayed until progression [5,24].
Astner et al. [16] described TV shrinkage by evaluating
the initial and follow-up volumetric data of irradiated
Figure 3. (0) Baseline MRI (for treatment planning) and follow-up MRIs after one (1) and two years (2) after RT by photons (A), protons (B) and after a combined RT
by photons and carbon ions according to the MARCIE-protocol (C).
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meningiomas. They measured the TVs of 53 FSRT and six
SRT-treated patients. For the FSRT-treated group the mean
follow-up period was 49.5 months (range 11–95 months) and
the mean relative size reduction was 25.5% (range 0–69.6%).
They observed significant relative tumor shrinkage of 17%
after 24, 23% after 24–48, 30% after 48–72 and 26% after
more than 72 months, respectively. However, they did not
observe any additional reduction after more than 72 months,
which might be the effect of a smaller number of available
MRIs in further follow-up. A significant TV shrinkage was
detected by Henzel et al. as well [17]. They prospectively
observed 84 FSRT-treated patients with grade I meningiomas.
They found a significant linear reduction of the volumes on
every follow-up after 6, 12, 18, 24, and 36 months with
16.6%, 24.5%, 27.9%, 33.2% and 36.0% respectively. Henzel
et al. predict a continuous decrease towards a steady state
which they still could not describe.
These results are comparable to our data. In our FSRT-
treated patients we observed similar significant TV shrinkage.
The relative size of the residual contrast enhancing TV was
84.0 ± 22.9% (p¼ .042) and 76.9 ± 14.6% (p¼ .001) at one-
and two-year follow-up, respectively. Similar volumetric
decreases were observed after irradiation with the other
applied RT modalities.
This is the first study that compares the TV shrinkage of
meningiomas according to different RT modalities. We could
not demonstrate any significant difference in volume reduc-
tion depending on the applied radiation quality. IMRT and
FSRT were administered with the similar median dose (56Gy,
range 39.6–60Gy) in 1.8 or 2 Gy daily fractions. These photon
techniques have already shown their positive effect on local
control, disease-free (DFS) and OS rates without major tox-
icity [5–10,12,23]. Henzel et al. could not demonstrate any
correlation between the TV shrinkage and the delivered radi-
ation doses [17]. They applied a median dose of 56Gy (range
50.4–59.4 Gy). Our delivered equivalent proton irradiation
doses were similar to the photon protocols (median 56 GyE;
range 54–58Gy) applied in 1.8 or 2 GyE daily fractions.
Carbon ions were applied in a mixed photon/carbon ion
scheme according to the MARCIE protocol [15]. Although a
carbon ion boost combined with photon irradiation gave the
option of dose escalation in the target volume, we could not
observe higher TV reduction. Nevertheless, we have to under-
line the benefits of particle therapy due to dose reduction in
the neighboring OARs. As patients suffering from meningio-
mas have long lifetime expectancy, the avoidance of late
side effects such as second malignancies, neurocognitive def-
icits or vascular events is particularly important [25].
For the first time volumetric tumor regression after RT
according to the WHO grade was analyzed. The incidence of
grade II tumors is approximately 5–7% of all meningiomas
and the occurrence of grade III tumors is 0.17/100 000/year
[1]. Among our patients the incidence of grade III meningio-
mas was 6.5% (5/77), which is higher than expected.
Interestingly, we observed significantly higher TV shrinkage
in these patients both at one- and two-year follow-up in
comparison to grade I meningiomas and the group of
patients with the unknown histology (Figure 5). The reason
could be the increased proliferation and decreased regener-
ation of anaplastic cells leading to higher radiation sensitivity.
On the contrary, higher grade is stated to be a negative
prognostic factor in respect of DFS and OS [1,3,6,12].
Both men and women showed significant TV reduction at
both follow-up examinations. Interestingly, we have found sig-
nificantly higher TV shrinkage among men. Although male
gender is an unfavorable prognostic factor in respect of OS
[1], in our patient cohort men presented higher TV shrinkage
(Figure 4), however, this might not correlate with the survival.
We did not observe any difference in TV shrinkage after
RT in correlation to operability. In our patient group
there were 22/77 inoperable (mean initial TV Vmean¼
22.2 ± 15.1 cm3) and 55/77 previously operated patients
(mean initial TV Vmean¼ 31.3 ± 25.6 cm3). Both groups showed
TV shrinkage at the follow-up examinations: the size of the
residual volumes were 89.6 ± 19.9% and 81.7 ± 6.6% for inop-
erable and 83.9 ± 21.6% and 75.0 ± 19.1% for operated
patients at one- and two- year follow-up, respectively. These
findings correspond with Astner et al. [16] and Henzel et al.
[17] who also could not find any predictive correlation
between TV shrinkage after RT and operability.
Conclusion
Evaluation of contrast enhancing tumor size after RT of men-
ingiomas using MRI-based volumetric measurements is a pre-
cise method to detect tumor regression. We have observed
significant TV shrinkage independently of the applied
Figure 4. Relative TV changes according to gender.
Figure 5. Relative TV changes according to WHO grade.
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radiation modality. TV shrinkage can be detected one and
two years after irradiation. WHO grade and gender appear to
be determining factors for TV shrinkage. Neither previous sur-
gery, age nor size of the initial TV influence TV reduction.
Further long-term follow-up is recommended to determine
whether size reduction correlates with DFS and OS rates.
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